Pfizer, Inc. · NYSE:PFE

Pfizer — Cowen and Company 29th Annual Health Care Conference 2009

17 slides from Pfizer's conference presentation, Mar 18, 2009

  1. Slide 1: Cowen and Company 29th Annual Health Care Conference

    Cowen and Company 29th Annual Health Care Conference March 18, 2009

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information „ Discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward- looking statements. The factors that could cause actual results to differ are discussed

  3. Slide 3: Additional Information on Proposed Wyeth Acquisition

    Additional Information on Proposed Wyeth Acquisition In connection with the proposed acquisition of Wyeth, Pfizer will file with the SEC a Registration Statement on Form S-4 that will include a proxy statement of Wyeth that also constitutes a prospectus of Pfizer. Wyeth will mail the proxy statement

  4. Slide 4: Jeff Kindler

    Jeff Kindler Chairman and Chief Executive Officer

  5. Slide 5: Olivier Brandicourt

    Olivier Brandicourt President – Specialty Care

  6. Slide 6: Specialty Care Business Unit

    Specialty Care Business Unit Spirit of a start-up Culture Entrepreneurial Customer-focused Agile Deliver Innovative Products Extraordinary Value Customers Academic medical centers Data-driven specialists Pharmacy 6 Creating the World’s Premier Biopharmaceutical Company

  7. Slide 7: Treating Patients Across a Wide Range of Conditions

    Treating Patients Across a Wide Range of Conditions Ophthalmology 9.3 MM patients 1.2 MM patients treated worldwide treated worldwide in one-year period in one-year period (MAT 09/08) (09/08) PAH/PVD Psychiatry Over 12,000 patients treated 2.2 MM patients treated (US, EU) Specialty worldwide since l

  8. Slide 8: Garry Nicholson

    Garry Nicholson President – Oncology

  9. Slide 9: Oncology Business Unit

    Oncology Business Unit „ Our mission is to cure or control cancer with breakthrough Mission medicines. Working together, we will advance the science to deliver the right drug, at the right time for each patient. „ Become a top 3 leader in Oncology by 2018 measured by Target our revenue, reputation a

  10. Slide 10: Frank D’Amelio

    Frank D’Amelio Chief Financial Officer

  11. Slide 11: Top Investor Discussion Topics

    Top Investor Discussion Topics „ Syndication Status „ Debt Issuance for Deal Financing „ Integration Process and Progress „ Financial Priorities and Considerations Given Strong Cash Flow Target in 2012 „ Regulatory Pathway for Approval „ 2012 Revenue Target 11 Creating the World’s Premier Biopharmac

  12. Slide 12: Funding

    Funding Obtain $22.5 billion funding commitment (bridge facility) from 5 banks; each with $4.5 billion Meet with various banks to syndicate debt to a broader group; minimize exposure to any one bank Complete the debt syndication – Commitments from 34 banks; none with a balance greater than $1.5 bill

  13. Slide 13: Integration Planning Core Principles

    Integration Planning Core Principles Our Approach Our Expectations „ Quickly create clarity about the „ Rapidly capture cost and end-state revenue synergies „ Execute a disciplined and „ Retain key talent from both transparent integration process Pfizer and Wyeth „ Pfizer BU model with „ No disrupti

  14. Slide 14: Integration Planning Off to a Successful Start

    Integration Planning Off to a Successful Start Executive Leadership Teams Have Met Launched Central Program Management Office Launched Joint Pfizer-Wyeth Workstream Teams Very Positive Initial Interactions with Wyeth Personnel 14 Creating the World’s Premier Biopharmaceutical Company

  15. Slide 15: Financial Priorities

    Financial Priorities $20+B in Operating Cash Flow with Net Cash Position Targeted in 2012 Reinvest to Support Repay Debt EPS Growth Maintain Flexibility Repatriate Less Dividend Payment Offshore Cash Share Repurchase 15 Creating the World’s Premier Biopharmaceutical Company

  16. Slide 16: Top Investor Discussion Topics

    Top Investor Discussion Topics „ Syndication Status „ Debt Issuance for Deal Financing „ Integration Process and Progress „ Financial Priorities and Considerations Given Strong Cash Flow Target in 2012 „ Regulatory Pathway for Approval „ 2012 Revenue Target 16 Creating the World’s Premier Biopharmac

  17. Slide 17: The Premier Global Biopharmaceutical Company

    The Premier Global Biopharmaceutical Company 17 Creating the World’s Premier Biopharmaceutical Company

Pfizer — Cowen and Company 29th Annual Health Care Conference 2009 on 6ix